Edition:
India

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

1.56USD
20 Apr 2018
Change (% chg)

$0.06 (+4.00%)
Prev Close
$1.50
Open
$1.50
Day's High
$1.56
Day's Low
$1.50
Volume
1,882
Avg. Vol
87,612
52-wk High
$3.75
52-wk Low
$0.78

Chart for

About

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $34.19
Shares Outstanding(Mil.): 16.21
Dividend: --
Yield (%): --

Financials

BRIEF-Aeterna Zentaris Qtrly Loss Per Share $0.03

* AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATING RESULTS

28 Mar 2018

BRIEF-Aeterna Zentaris Appoints James Clavijo As CFO

* AETERNA ZENTARIS APPOINTS JAMES CLAVIJO AS CHIEF FINANCIAL OFFICER

06 Mar 2018

BRIEF-Aeterna Zentaris Provides Update On Previously Disclosed Class Action Lawsuit

* AETERNA ZENTARIS PROVIDES UPDATE ON PREVIOUSLY DISCLOSED CLASS ACTION LAWSUIT

05 Mar 2018

BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada

* AETERNA ZENTARIS ENTERS INTO LICENSING AND ASSIGNMENT AGREEMENT WITH STRONGBRIDGE FOR MACRILEN™ (MACIMORELIN) IN THE U.S. AND CANADA

17 Jan 2018

BRIEF-Aeterna Zentaris Provides Update On Litigation Against David Dodd And Philip Theodore

* AETERNA ZENTARIS PROVIDES UPDATE ON LITIGATION AGAINST DAVID DODD AND PHILIP THEODORE

23 Dec 2017

BRIEF-David Dodd And Philip Theodore Respond To Claim By Aeterna Zentaris

* DAVID DODD AND PHILIP THEODORE RESPOND TO CLAIM BY AETERNA ZENTARIS

22 Dec 2017

Canada's Aeterna gets FDA approval for growth hormone deficiency test

Canada's Aeterna Zentaris Inc said on Wednesday the U.S. Food and Drug Administration has approved its oral test to diagnose adult growth hormone deficiency.

21 Dec 2017

Canada's Aeterna gets FDA approval for growth hormone deficiency test

Dec 20 Canada's Aeterna Zentaris Inc said on Wednesday the U.S. Food and Drug Administration has approved its oral test to diagnose adult growth hormone deficiency. The company said it intends to launch the test, Macrilen, in the United States during the first quarter of 2018.

21 Dec 2017

BRIEF-Aeterna Zentaris Announces FDA Approval Of Macrilen For Diagnosis Of Adult Growth Hormone Deficiency

* AETERNA ZENTARIS ANNOUNCES FDA APPROVAL OF MACRILEN™ (MACIMORELIN) FOR DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY

21 Dec 2017

BRIEF-Aeterna Zentaris Announces Departure Of Interim Chief Financial Officer

* AETERNA ZENTARIS ANNOUNCES DEPARTURE OF INTERIM CHIEF FINANCIAL OFFICER

08 Dec 2017

Earnings vs. Estimates